A nova orientação da Team-NB sobre a qualificação de software no âmbito do IVDR fornece critérios claros para que os fabricantes de software médico saibam quando uma aplicação se qualifica como dispositivo de diagnóstico in vitro (IVD MDSW). Com exemplos práticos e fluxogramas, o documento diferencia software autónomo, acessórios e ferramentas não qualificadas.

The new revised version of the MDCG 2019-11 (Rev.1) clarifies the qualification and classification of software as a medical device (MDSW ) and in vitro diagnostic software (IVD), in the context of the MDR and IVDR. The document covers classification rules, integration with AI Act and EHDS, and includes practical and up-to-date examples. Smart MDR supports MDSW manufacturers in managing compliance and technical documentation.

The new MDCG 2025-6 guide, published in June 2025, clarifies the joint application of the AI Act and the European MDR/IVDR regulations for medical devices and IVDs with artificial intelligence systems. The document addresses classification, risk management, life cycle, technical documentation and post-market monitoring. Smart MDR supports manufacturers in integrating these requirements into their quality management system and preparing for audits.

The MDCG has published guidance 2025-4, which clarifies the responsibilities of manufacturers of software as a medical device (MDSW) and operators of online platforms that make these apps available in the European Union. The guidance addresses the application of the MDR, the IVDR and the Digital Services Act (DSA), and reinforces labeling, traceability and transparency requirements. Smart MDR supports manufacturers and platforms in regulatory compliance and adaptation to the new obligations of the European digital market.